TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00302211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Iloprost (5 μg)
Description: iloprost inhalation solution (Ventavis) (5 μg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Iloprost (5 μg)
Description: iloprost inhalation solution (Ventavis) (5 μg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Iloprost (5 μg)
Description: iloprost inhalation solution (Ventavis) (5 μg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Iloprost (5 μg)
Description: iloprost inhalation solution (Ventavis) (5 μg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Placebo
Description: inhaled placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: inhaled placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: oral sildenafil (dosage between 60 and 300 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: oral sildenafil (dosage between 60 and 300 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: oral sildenafil (dosage between 60 and 300 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: oral bosentan (dosage between 62.5 and 125 mg BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: oral bosentan (dosage between 62.5 and 125 mg BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bosentan
Description: oral bosentan (dosage between 62.5 and 125 mg BID)
Study: NCT00751803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 TA Low Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eletriptan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 TA Medium Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 TA Medium Dose
Study: NCT03186027

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10 plus NADH
Description: Active arm: Coenzyme Q10 plus NADH CFS/ME patients who will be randomized to measure the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH 20 mg/day; 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: Reconnect

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: phosphoserine plus vitamin C
Description: Placebo arm: phosphoserine plus vitamin C CFS/ME patients who will be randomized to measure the effect of oral Placebo supplementation (phosphoserine and vit C, 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: placebo
Study: NCT02452424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: PLX3397 capsules, 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: PLX3397 capsules, 200 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg, IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg, IV
Study: NCT03612167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive intervention
Description: a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutritional group
Description: 12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
Study: NCT03222375

Intervention type: DEVICE
Intervention: SQUED™ series 28.1 home-use
Description: Semiconducting QUantum Excitonic Device - artifificial active medium, where the processes of self-organization lead to creation and converter of Autowaves energy.~Some autowaves have the properties of quasi-particles!
Study: NCT03871127

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: Using sirolimus eluting stent

Intervention type: PROCEDURE
Intervention: coronary artery bypass graft
Description: coronary artery bypass graft
Study: NCT04695938

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: MRI examination with Black Bone, and ultrashort/zero echo time MRI techniques
Study: NCT02150564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonowand
Description: Initially a 2D acquisition will be performed and ultrasound parameters adjusted to obtain the best image resolution. Then anatomical landmarks will be identified if possible and the lesioncharacterized. Once the lesion is identified a rapid 3D-US acquisition will be performed. Tumor resection will proceed guided by the 3D US images using a trackable pointer to navigate. Repeat 3D US images will be obtained as many times as required during the surgery to update the information as tumor debulking proceeds. A final US will be obtained at the end of the procedure and after dural closure

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Navigation
Description: Routine microneurosurgical procedures would be adopted in all cases.Sonowand system will be used for navigation control arm as well as sononavigation experimental arm. Image registration (on the previously imported DICOM images) will be done on the system and after positioning, patient-toimage registration will be completed. The Registration accuracy will be documented.
Study: NCT02871128

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natureheme-iron
Description: An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg starch placebo of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: supplement
Description: An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 1 capsule per day containing either 100 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
Study: NCT00322010

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early PT OT
Description: 1. Passive range of motion exercises for all limbs in patients who remain unresponsive despite sedative interruption (ten repetitions in all cardinal directions).~2. Sessions began with active assisted and active range of motion exercises in the supine position.~3. If tolerated, treatment is advanced to bed mobility activities, including transferring to upright sitting.~4. Sitting balance activities are followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~5. The session progresses to transfer training, and finally pre-gait exercises and ambulation.~6. Progression of activities is dependent on patient tolerance and stability.~7. Therapy intervention continues on a daily basis throughout the patient's hospital stay until he/she returns to prior level of function or is discharged.
Study: NCT01331616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Description: Dosage is: 10 mg/kg every 2 weeks as monotherapy or in combination (unlabeled) with irinotecan. Patients will also receive Radiotherapy prior to beginning chemotherapy.
Study: NCT03323528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzalkonium Chloride-Benzocaine Topical
Description: Dorithricin = tyrothricin, benzalkonium chloride, benzocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet = a lozenge with matched appearance and the same excipients as Active Comparator Dorithricin lozenge.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day.
Study: NCT02259933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03907683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Message with Text and Optional Image
Description: Messages can be up to 256 characters of text and with or without an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity).
Study: NCT02579746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASHNa-CC
Description: The 8-week DASHNa-CC intervention incorporated Dietary Approach to Stop Hypertension (DASH) diet, sodium reduction with the food therapy of Traditional Chinese Medicine, and included an intervention manual, two sessions of classroom instruction delivered in Mandarin, and a 20-minute telephone follow-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: education booklet, encouragement of physician visit, use of public health resources if needed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: usual care
Description: education booklet, encouragement of physician visit, use of public health resources if needed
Study: NCT02310178

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bariatric surgery
Description: all of the current bariatric surgeries are allowed in this prospective cohort study
Study: NCT04770376

Intervention type: OTHER
Intervention: Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy.
Description: Collection of blood samples during blood draws performed before each cycle of chemotherapy as per clinical practice.

Intervention type: OTHER
Intervention: Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy.
Description: Collection of blood samples during blood draws performed before each cycle of chemotherapy as per clinical practice.
Study: NCT00983554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrazole
Description: Arimidex 1mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testim 10g daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testim 10g daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testim 10g daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Avodart 2.5mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Avodart 2.5mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Avodart 2.5mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: Acyline 300 µg/kg subcutaneous injections every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: Acyline 300 µg/kg subcutaneous injections every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: Acyline 300 µg/kg subcutaneous injections every 2 weeks
Study: NCT02349802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syringe with exenatide suspension
Description: A flexible study design to accommodate multiple cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syringe with exenatide suspension
Description: A flexible study design to accommodate multiple cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syringe with exenatide suspension
Description: A flexible study design to accommodate multiple cohorts.
Study: NCT01248663

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: antecolic reconstruction
Description: see study arm description

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retrocolic reconstruction
Description: see study arm description
Study: NCT01803945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVE8112

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03778606

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potato starch
Description: Potato starch will be given twice a day for up to 14 days, discharge, or death, whichever occurs first.
Study: NCT03339609

Intervention type: DIAGNOSTIC_TEST
Intervention: Uroflow
Description: Isolated uroflow measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Uroflow/EMG
Description: Uroflow measurement with superficial EMG testing of the pelvic floor
Study: NCT02948686

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Etching Application Strategy
Description: In Group SET, the adhesive system Ambar Universal will be used in 55 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enamel Etching Application Strategy
Description: In Group SEE, 37% phosphoric acid will be applied during 15 seconds, only in enamel in 55 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Ambar Universal will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self Etching with Extended time Application Strategy
Description: In Group SETT, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 20 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self Etching with Extended layers number Strategy
Description: In Group SETL, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
Study: NCT02332421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified dentoalveolar distractor
Description: Here, the modified distractor is going to be used when retracting the canine.
Study: NCT04064840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVF: Decapeptyl and hCG
Description: When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FET: Decapeptyl
Description: On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IVF: hCG and normal saline
Description: When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FET: Normal Saline
Description: On the day of FET, normal saline will be injected subcutaneously.
Study: NCT03416023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIES® (Transcutaneous Implant Evacuation System)
Description: Transcutaneous Implant Evacuation System
Study: NCT03401827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Gemcitabine + nab-paclitaxel)
Description: Nanoparticle albumin-bound paclitaxel (125 mg/m2) miv over 30 min, Day 1,8,15~Gemcitabine (1,000mg/m2) and N/S 150mL miv over 30 min, Day 1,8,15
Study: NCT01758991

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS is a safe and painless transcranial stimulation that modulates brain activity and could improve stroke recovery. Electrodes in soaked sponges are placed over specific brain regions and held with an elastic band. Direct current is then applied through the electrodes. The patients may feel nothing or a slight tingling under the electrodes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS is a safe and painless transcranial stimulation that modulates brain activity and could improve stroke recovery. Electrodes in soaked sponges are placed over specific brain regions and held with an elastic band. Direct current is then applied through the electrodes. The patients may feel nothing or a slight tingling under the electrodes.
Study: NCT04044404

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography)
Description: Compare the ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography) with the diagnostic gold standard of kidney disease---kidney biopsy

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography)
Description: Compare the ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography) with the diagnostic gold standard of kidney disease---kidney biopsy

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography)
Description: Compare the ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography) with the diagnostic gold standard of kidney disease---kidney biopsy
Study: NCT01875900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video-assisted learning and self-directed training
Description: The Neonatal Resuscitation Program (NRP) DVD will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based neonatal resuscitation training
Description: Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
Study: NCT00889928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOTES GEN 1 Toolbox
Description: * Articulating Hook Knife~* Articulating Snare~* Articulating Needle Knife~* Articulating Graspers~* Articulating Biopsy Forceps~* Steerable Flex Trocar with Rotary Access Needle~* Flexible Bipolar Hemostasis Forceps~* Flexible Maryland Dissector
Study: NCT02288949

Intervention type: OTHER
Intervention: stratification
Description: Patients will be stratified based on the values of relevant demographics, pulmonary and systemic variables in relation to mortality in the intensive care unit.
Study: NCT03792880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telematic control and self-management program
Description: During 6 months with CPAP treatment, patients must complete some questionnaires about the presence of refreshing sleep and side effects with the frequency established, using a computing application. Patients can download this application on their own smartphone but, if they prefer, they can be provided with a tablet during the study with this application installed.~A set of variables will be collected using an automatic and wireless transmission from latest generation CPAP to control the CPAP compliance and tolerance. All data will be processed in a platform to generate alarms, which will be controled daily by a researcher, as well as solutions to the problems presented during the monitoring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habitual follow-up in Healthcare System
Description: According to the SEPAR regulation, patients treated with CPAP should be evaluated by the pulmonologist one month after beginning treatment, every 3 months during the first year, every 6 months during the second year and annually from the third year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habitual follow-up in Healthcare System
Description: According to the SEPAR regulation, patients treated with CPAP should be evaluated by the pulmonologist one month after beginning treatment, every 3 months during the first year, every 6 months during the second year and annually from the third year.